Decision on IPR: Oct 24, 2018
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Status
|
|
IPR2018-01550
|
08/21/2018
|
—
|
Par Pharmaceutical, Inc.
|
9,561,197
|
Horizon Therapeutics
|
Terminated-Settled
|
On’197 patent, Lupin field IPR (IPR2018-00459) on 01/12/2018 which was terminated due to settlement on July 25, 2018.
US 9,561,197 (Horizon Therapeutics, LLC; Exp: 09/22/2030) – OB listed
1. A method of treating a urea cycle disorder in a subject comprising administering to a subject having a plasma PAA to PAGN ratio outside the target range of 1 to 2, a dosage of glyceryl tri-[4-phenylbutyrate] (HPN-100) effective to achieve a plasma PAA to PAGN ratio within the target range of 1 to 2.
2. A method of treating a urea cycle disorder in a subject comprising administering to a subject having a plasma PAA to PAGN ratio outside the target range of 1 to 2.5, a dosage of glyceryl tri-[4-phenylbutyrate] (HPN-100) effective to achieve a plasma PAA to PAGN ratio within the target range of 1 to 2.5.
Leave a Reply